The Role of Complement in Cancer Immunotherapy
活動訊息
中文書、漫畫輕小說5折起、電子書35元起，全館滿$1,000送100點金幣
內容簡介
The dual role of complement in both cancer development and treatment has been investigated extensively and is characterized by a substantial literature that documents the conditions in which complement can either enhance tumor growth or promote the killing of malignant cells. Indeed, there are now numerous examples of monoclonal antibodies (mAbs) that have either been approved by the FDA or that are under active investigation that make use of complement when eliminating cancer cells. Although the direct in vitro killing of mAb-opsonized cancer cell lines by complement-dependent cytotoxicity (CDC) can be readily demonstrated, there are considerable challenges related to the translation of these findings to the clinic, and numerous strategies have been employed to maximize mAb-mediated CDC in cancer treatment. These approaches include the redesign of mAb dosing schedules; engineering the Fc regions of the mAbs to enhance complement activation; treatment with cocktails of mAbs that bind to several different sites on the targeted cells and thus that potentially synergize CDC promotion; and neutralizing the complement control proteins on malignant cells to weaken their defenses against complement. Target sites on malignant cells that have been successfully exploited for mAb-induced CDC include CD20, CD37, CD38, CD52, and Epidermal Growth Factor Receptors. MAbs specific to complement components have served as powerful analytical reagents to investigate the detailed mechanisms of CDC, and they have been employed to document complement activation by cancer cells and to examine the role of complement proteins (in particular C1q and fragments of C3 and C5) in supporting tumor growth. The use of polyclonal and mAb reagents has revealed a role for the intracellular complement system in cancer biology and strategies that focus on the interaction of complement with the tumor microenvironment, and examining the impact of the complotype on the response to immunotherapy in cancer should lead to additional mAb-based therapies. Along these lines, there is now increasing evidence that strategies that make use of mAbs or other agents to modulate the action of C3a/C5a or their respective receptors may also find use in cancer immunotherapy.
配送方式
-
台灣
- 國內宅配：本島、離島
-
到店取貨：
-
海外
- 國際快遞：全球
訂購/退換貨須知
加入金石堂 LINE 官方帳號『完成綁定』，隨時掌握出貨動態：
商品運送說明：
- 本公司所提供的產品配送區域範圍目前僅限台灣本島。注意！收件地址請勿為郵政信箱。
- 商品將由廠商透過貨運或是郵局寄送。消費者訂購之商品若無法送達，經電話或 E-mail無法聯繫逾三天者，本公司將取消該筆訂單，並且全額退款。
- 當廠商出貨後，您會收到E-mail出貨通知，您也可透過【訂單查詢】確認出貨情況。
- 產品顏色可能會因網頁呈現與拍攝關係產生色差，圖片僅供參考，商品依實際供貨樣式為準。
- 如果是大型商品（如：傢俱、床墊、家電、運動器材等）及需安裝商品，請依商品頁面說明為主。訂單完成收款確認後，出貨廠商將會和您聯繫確認相關配送等細節。
- 偏遠地區、樓層費及其它加價費用，皆由廠商於約定配送時一併告知，廠商將保留出貨與否的權利。
提醒您！！
金石堂及銀行均不會請您操作ATM! 如接獲電話要求您前往ATM提款機，請不要聽從指示，以免受騙上當！
退換貨須知：
**提醒您，鑑賞期不等於試用期，退回商品須為全新狀態**
-
依據「消費者保護法」第19條及行政院消費者保護處公告之「通訊交易解除權合理例外情事適用準則」，以下商品購買後，除商品本身有瑕疵外，將不提供7天的猶豫期：
- 易於腐敗、保存期限較短或解約時即將逾期。（如：生鮮食品）
- 依消費者要求所為之客製化給付。（客製化商品）
- 報紙、期刊或雜誌。（含MOOK、外文雜誌）
- 經消費者拆封之影音商品或電腦軟體。
- 非以有形媒介提供之數位內容或一經提供即為完成之線上服務，經消費者事先同意始提供。（如：電子書、電子雜誌、下載版軟體、虛擬商品…等）
- 已拆封之個人衛生用品。（如：內衣褲、刮鬍刀、除毛刀…等）
- 若非上列種類商品，均享有到貨7天的猶豫期（含例假日）。
- 辦理退換貨時，商品（組合商品恕無法接受單獨退貨）必須是您收到商品時的原始狀態（包含商品本體、配件、贈品、保證書、所有附隨資料文件及原廠內外包裝…等），請勿直接使用原廠包裝寄送，或於原廠包裝上黏貼紙張或書寫文字。
- 退回商品若無法回復原狀，將請您負擔回復原狀所需費用，嚴重時將影響您的退貨權益。
商品評價